Figure 4. Tumor growth curves and immune cell profiles in various tissues.

Relative tumor size of (A) 1° tumor and (B) 2° tumor after one time i.t. injection. An arrow indicates injection date. Immune cells were profiled 18 d after inoculations of 1° tumors. Number of (C) CD45⁺CD11b⁺CD11c⁻Gr1⁺ MDSCs in 1° tumor. Number of immune cells in 1° dLN; (D) CD45⁺CD11b⁺CD11c⁺ DCs, (E) MHCII^+low, MHCII^+mid, and MHCII^+high CD45⁺CD11b⁺CD11c⁺ DCs, (F) CD45⁺CD11b⁺CD11c⁻Gr1⁺ MDSCs, (G) CD45⁺CD3⁺CD4⁺CD25⁺Foxp3⁺ Treg, (H) LAG-3⁺ CD45⁺CD3⁺CD4⁺ T cells, (I) LAG-3⁺ CD45⁺CD3⁺CD8⁺ T cells, (J) PD-1⁺ CD45⁺CD3⁺CD8⁺ T cells, (K) Tetramer+ CD45⁺CD3⁺CD8⁺ T cells, (L) CD45⁺CD11b⁺F4/80⁺ macrophages, and (M) CD45⁺CD3⁻NK1.1⁺ NK cells. Number of immune cells in spleen; (N) CD45⁺CD11b⁺CD11c⁺ DCs, (O) CD86⁺ CD45⁺CD11b⁺CD11c⁺ DCs, (P) MHCII^+low, MHCII^+mid, and MHCII^+high CD45⁺CD11b⁺CD11c⁺ DCs, (Q) CD45⁺CD11b⁺F4/80⁺CD86⁺ M1 macrophages, and (R) ratio of M1 to M2 (CD45⁺CD11b⁺F4/80⁺CD206⁺). Number of immune cells in 2° dLN; (S) CD86⁺ CD45⁺CD11b⁺CD11c⁺ DCs, (T) MHCII^+low, MHCII^+mid, and MHCII^+high CD45⁺CD11b⁺CD11c⁺ DCs, (U) CD45⁺CD11b⁺F4/80⁺ macrophages, (V) CD45⁺CD11b⁺F4/80⁺CD86⁺ M1 macrophages, and (W) CD45⁺CD11b⁺F4/80⁺CD206⁺ M2 macrophages. ****p<0.0001, ***p<0.001, **p<0.01, and *p<0.05.